title: Pharmaceutical Approval Update.
abstract: Sacubitril/valsartan (Entresto) for chronic heart failure; brexpiprazole (Rexulti) for major depressive disorder and schizophrenia; and lumacaftor/ivacaftor (Orkambi) for cystic fibrosis involving specific CFTR mutations.
authors.forename: Kunj
authors.initials: K
authors.lastname: Gohil